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Cytokinesis of animal cells requires ingression
of the actomyosin-based contractile ring be-
tween segregated sister genomes. Localization
of the RhoGEF Ect2 to the central spindle at
anaphase promotes local activation of the
RhoA GTPase, which induces assembly and in-
gression of the contractile ring. Here we have
used BI 2536, an inhibitor of the mitotic kinase
Plk1, to analyze the functions of this enzyme
during late mitosis in human cells. We show
that Plk1 acts after Cdk1 inactivation and inde-
pendently from Aurora B to promote RhoA
accumulation at the equator, contractile ring
formation, and cleavage furrow ingression. Inhi-
bition of Plk1 abolishes the interaction of Ect2
with its activator and midzone anchor, HsCyk-
4, thereby preventing localization of Ect2 to
the central spindle. We propose that latemitotic
Plk1 activity promotes recruitment of Ect2 to
the central spindle, triggering the initiation of
cytokinesis and contributing to cleavage plane
specification in human cells.
INTRODUCTION
During cytokinesis of animal cells, constriction of the acto-
myosin-based contractile ring drives ingression of the
cleavage furrow between the two sets of segregated sister
chromatids at anaphase (Eggert et al., 2006; Glotzer,
2005). Subsequent membrane fusion generates two phys-
ically distinct daughter cells. Formation of the contractile
ring at the equatorial cortex requires local activation of
the Rho family GTPase RhoA, which induces actin poly-
merization andmyosin II activation (Kamijo et al., 2006; Ki-
mura et al., 2000; Piekny et al., 2005; Yoshizaki et al.,
2003; Yuce et al., 2005). To avoid the generation of aneu-
ploid daughter cells, cytokinesis has to be subject to spa-
tial and temporal controls (Storchova and Pellman, 2004).
Cytokinesis failure in murine cells leads to progressive ge-
nomic instability and tumorigenesis (Fujiwara et al., 2005).DevelopThe induction of cytokinetic events at the cortex re-
quires signaling from the central spindle (also known as
the spindle midzone), a structure formed between segre-
gated chromatids at anaphase onset by bundles of inter-
digitating antiparallel microtubules (Eggert et al., 2006;
Glotzer, 2005). The conserved Rho guanine nucleotide ex-
change factor (GEF) Ect2 (called Pebble in Drosophila,
LET-21 in nematodes) plays a central role in the signaling
from the midzone to the cortex, which specifies the cleav-
age plane (Dechant and Glotzer, 2003; Nishimura and
Yonemura, 2006; Prokopenko et al., 1999; Tatsumoto
et al., 1999; Yuce et al., 2005; Zhao and Fang, 2005). At
anaphase, Ect2 binds to HsCyk-4 (also known as
MgcRacGAP) and localizes to the midzone (Nishimura
and Yonemura, 2006; Somers and Saint, 2003; Yuce
et al., 2005; Zhao and Fang, 2005). Together with the kine-
sin-6 Mklp1, HsCyk-4 forms the centralspindlin protein
complex, which is essential for midzone formation
(Mishima et al., 2002). Ect2 binding to the centralspindlin
subunit HsCyk-4 at anaphase recruits Ect2 to themidzone
and is thought to stimulate its catalytic activity (Nishimura
and Yonemura, 2006; Somers and Saint, 2003; Yuce et al.,
2005; Zhao and Fang, 2005). Consequently, Ect2 signals
to the overlying equatorial cortex by activating RhoA,
leading to contractile ring formation and cleavage furrow
ingression.
In early mitosis, cyclin-dependent kinase 1 (Cdk1)
bound to cyclin B inhibits cytokinesis and mitotic exit
and, thus, ensures that these processes do not occur prior
to anaphase onset (Eggert et al., 2006). At the meta- to
anaphase transition, the anaphase promoting complex
or cyclosome (APC/C) induces the coordinated degrada-
tion of cyclin B and the anaphase inhibitor securin and
thereby facilitates chromosome segregation, cytokinesis,
and mitotic exit (Eggert et al., 2006). Cdk1/cyclin B blocks
cytokinesis by inhibiting the microtubule bundling activity
of midzone-associated proteins (Mishima et al., 2004; Zhu
et al., 2006) and by preventing the interaction of Ect2 with
HsCyk-4 (Yuce et al., 2005). How mitotic kinases contrib-
ute to cleavage plane specification and coordinate cell-
cycle progression with local cytoskeletal activity during
cytokinesis is poorly understood.
Polo-like kinases (Plks) are highly conserved eukaryotic
serine/threonine kinases that were originally identified inmental Cell 12, 713–725, May 2007 ª2007 Elsevier Inc. 713
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Plk1 Triggers Cytokinesis in Human CellsDrosophila (Sunkel and Glover, 1988) and are essential for
mitosis in all organisms analyzed to date (Barr et al., 2004;
van de Weerdt and Medema, 2006). Plks contain a car-
boxy-terminal polo box domain (PBD) that acts as a phos-
phopeptide binding module and target Plks to subcellular
locations previously marked by phosphorylation (Barr
et al., 2004; van de Weerdt and Medema, 2006). Human
Plk1 regulates a multitude of early mitotic processes, in-
cluding centrosome maturation, formation of bipolar spin-
dles, andmicrotubule/kinetochore interactions (Barr et al.,
2004; Lenart et al., 2007; McInnes et al., 2006; Peters
et al., 2006; Sumara et al., 2004; van de Weerdt and Me-
dema, 2006). Consistent with its many functions during
mitosis, Plk1 localizes to centrosomes, kinetochores,
and later to the midzone (Barr et al., 2004). Owing to its
multiple functions in spindle assembly, compromising
Plk1 function in human cells leads to a prominent prome-
taphase-like arrest, which is dependent on the spindle as-
sembly checkpoint (SAC) (Lenart et al., 2007; McInnes
et al., 2006; Peters et al., 2006; Sumara et al., 2004; van
Vugt et al., 2004). Typically, arrested cells contain amono-
polar spindle and ring-shaped arrangement of chromo-
somes (‘‘Polo arrest’’). These defects prevent cell-cycle
progression past the meta- to anaphase transition and
preclude direct analysis of Plk1 function during later mi-
totic events, such as cytokinesis. Based on analogy to
yeast (Mulvihill et al., 1999; Ohkura et al., 1995; Song
and Lee, 2001; Yoshida et al., 2006), the analysis of a hy-
pomorphic allele in flies (Carmena et al., 1998), indirect
data and SAC override experiments in mammalian cells
(Aumais et al., 2003; Fabbro et al., 2005; Litvak et al.,
2004; Neef et al., 2003; Seong et al., 2002; van Vugt
et al., 2004; Zhou et al., 2003), and Plk1 localization to
the midzone, Plk1 has been implicated in regulating cyto-
kinesis in animal cells (Barr et al., 2004; van deWeerdt and
Medema, 2006). However, the consequences of complete
and anaphase-specific inactivation of Plk1 and the poten-
tial underlying molecular functions of the kinase were
hitherto unknown.
Recently developed small-molecule inhibitors for Plk1
(McInnes et al., 2006; Peters et al., 2006; Steegmaier
et al., 2007) allow precise temporal control over Plk1 en-
zyme inactivation in vivo and facilitate the direct analysis
of Plk1 function during latemitosis. The small-molecule in-
hibitor BI 2536 (see Figure S1A in the Supplemental Data
available with this article online), which is being developed
as an anticancer drug, blocks Plk1 activity with high
potency in vitro (IC50 = 0.8 nM) (Steegmaier et al., 2007).
Except for twomembers of the human Plk family, the com-
pound does not show significant inhibition toward a large
panel of other human kinases (Steegmaier et al., 2007).
Crucially, treatment of human cells prior to mitotic entry
with 100 nM BI 2536 recapitulates all known early mitotic
phenotypes of Plk1 deficiency with full penetrance and
rapid phenotype onset, without inducing phenomena
that are incompatible with functions ascribed to Plk1 (Le-
nart et al., 2007; Steegmaier et al., 2007). Thus, BI 2536
treatment might allow complete and specific inhibition of
Plk1 enzyme activity in cultured cells. Here we have714 Developmental Cell 12, 713–725, May 2007 ª2007 Elsevieused BI 2536 to analyze the function of Plk1 in regulating
processes after anaphase onset. Our chemical biology
analysis identified Plk1 as a key regulator of early cyto-
kinetic events in human cells.
RESULTS
The Plk1 Inhibitor BI 2536 Blocks the Initiation
of Cytokinesis in Human Cells
To specifically inhibit Plk1 activity during late mitosis, we
arrested HeLa cells in a metaphase-like state using the
proteasomal inhibitor MG132 (Figure 1A). Removal of
MG132 resulted in a synchronous wave of anaphase (Fig-
ure S1B). Addition of the Plk1 inhibitor BI 2536 (100 nM)
20 min after release from metaphase avoided trapping
cells in a prometaphase Polo arrest and allowed the
majority of cells to undergo anaphase (Figure S1D). Never-
theless, this treatment was sufficient to inhibit Plk1 activity
by the time of anaphase completion (Figure S1E), as
judged by one hallmark of Plk1 deficiency (Barr et al.,
2004): the disappearance of g-tubulin from centrosomes
(Figure S1C). Thus, we chose this regimen to study Plk1
function during late mitosis.
To assess the consequences of Plk1 inactivation during
anaphase, we compared solvent-treated control and BI
2536-treated HeLa cells 12 hr after release from meta-
phase. At that time, both control and BI 2536-treated cells
had exited mitosis and assumed interphase morphology.
Whereas untreated cells contained a single nucleus, the
vast majority of BI 2536-treated cells were twice the size
of control cells and contained two individual nuclei, indic-
ative of failure in cytokinesis (Figure 1B, upper panel;
Figure S1E). This binucleation phenotype due to Plk1 inhi-
bition at anaphase was also observed in noncancer hu-
man retinal pigment epithelial (hTERT-RPE1) cells, which
contain a normal karyotype and have been immortalized
by expression of telomerase (Figure 1B, lower panel).
These data suggest that Plk1 activity at anaphase is es-
sential for cytokinesis but dispensable for bulk chromo-
some segregation and mitotic exit.
To characterize this cytokinesis defect in more detail,
we performed time-lapse analysis of HeLa cells which sta-
bly expressed a green fluorescent protein (GFP)-tagged
version of the core histone H2B and were treated with BI
2536 after release from metaphase. In control cells, in-
gression of the cleavage furrow shortly after anaphase on-
set separated the nascent daughter cells (Figures 1D and
1E; Movie S1). Despite successful chromosome segrega-
tion, no cleavage furrow ingression was detected in the
majority of BI 2536-treated cells, which subsequently
exited mitosis as binucleated cells (Figures 1D and 1E;
Movie S1). These time-lapse results were confirmed by
immunofluorescence microscopy (IFM) analysis of telo-
phase cells with decondensed chromatin, in which prior
treatment with BI 2536 caused a prominent failure in
cleavage furrow ingression (Figure 1C; Figure S1E). These
data demonstrate that BI 2536 blocks cytokinesis at a very
early stage and suggest that Plk1 controls the initiation of
cytokinesis in human cancer and noncancer cells.r Inc.
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Plk1 Triggers Cytokinesis in Human CellsFigure 1. The Plk1 Inhibitor BI 2536 Blocks the Initiation of Cytokinesis in Human Cells
(A) HeLa cell synchronization scheme for anaphase-specific inhibition of Plk1 by addition of BI 2536.
(B) Control or BI 2536-treated HeLa and hTERT-RPE1 cells were analyzed by immunofluorescencemicroscopy (IFM) 12 hr after release frommetaphase.
HeLa cells were treatedwith 100 nMBI 253620min after release, whereas hTERT-RPE1 cellswere treatedwith 250 nMBI 2536115min after release. The
scale bars in this and all subsequent images represent 10 mm. The percentage of binucleation observed in interphase cells is indicated (n > 100 cells).
(C) HeLa cells, which were treated with control solvent or 100 nM BI 2536 20 min after release frommetaphase, were analyzed by IFM 115 min after re-
lease. Percentage of telophase cells displaying furrow ingression among all telophase cells is indicated (n = 100).
(D) Selected frames from time-lapse series of HeLa cells stably expressing H2B-GFP. Cells were released frommetaphase and treated with control sol-
vent or 100 nM BI 2536 prior to recording. Drug treatment was performed 20 min after release from metaphase. Time point t = 0 min is set to anaphase
onset. For full movie, see Movie S1.
(E) Quantification of the experiment shown in (D). Cytokinesis phenotypes are shown in percentage of the number of cells that underwent anaphase and
exited mitosis during the time-lapse analysis (n = 59 for control, n = 66 for BI 2536).Developmental Cell 12, 713–725, May 2007 ª2007 Elsevier Inc. 715
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Plk1 Triggers Cytokinesis in Human CellsFigure 2. BI 2536 Abolishes Equatorial RhoA Localization and Contractile Ring Formation
(A) HeLa cells treated with control solvent or 100 nM BI 2536 20 min after release frommetaphase were analyzed for the localization of the contractile
ring marker anillin by IFM at anaphase and telophase. Representative images are shown. Percentages indicate the fraction of cells displaying the
phenotype represented by the image among all cells scored at that cell-cycle stage (n = 100).
(B) Cells were processed as in (A) but analyzed for the localization of myosin II.
(C) Cells were processed as in (A) but analyzed for the localization of RhoA.BI 2536 Abolishes Equatorial RhoA Localization
and Contractile Ring Formation
To investigate how BI 2536 blocks the initiation of cytoki-
nesis, we analyzed whether inhibition of Plk1 affected the
formation of the contractile ring at the equator during ana-
phase. In control cells, the contractile ring components
anillin and myosin II (Eggert et al., 2006; Glotzer, 2005)
were strongly enriched at the equatorial cortex at ana-
phase (Figures 2A and 2B); later, at telophase, anillin
was concentrated around the midbody, a dense microtu-
bule-associated structure found at the site of division
(Figure 2A). Treatment with BI 2536 at anaphase abolished
the localization of both anillin and myosin II to the equato-
rial cortex (Figures 2A and 2B). This strong defect in con-
tractile ring assembly upon Plk1 inhibition prompted us to
test the localization of the contractile ring regulator RhoA.
In control cells, RhoA localizes to the equatorial cortex at
anaphase and marks the cleavage furrow until telophase
(Figure 2C) (Yonemura et al., 2004). Strikingly, treatment
with BI 2536 at anaphase abolished the accumulation of716 Developmental Cell 12, 713–725, May 2007 ª2007 ElsevierRhoA at the equatorial cortex during anaphase and telo-
phase (Figure 2C), providing an explanation for the failure
in contractile ring assembly and the early cytokinesis de-
fect observed upon Plk1 inhibition. Taken together, our
data suggest that Plk1 kinase activity is crucial for the ear-
liest known cortical event during cytokinesis: the accumu-
lation and possibly activation of RhoA at the equator.
BI 2536 Treatment Does Not Prevent Cytokinesis
via Elevated Cdk1 Activity
Inhibition of Plk1 at anaphase might block cytokinesis in-
directly by interfering with APC/C activity and degradation
of cyclin B, which would prevent Cdk1 inactivation (Eggert
et al., 2006). However, in contrast to metaphase cells and
cells arrested with BI 2536 at prometaphase, IFM analysis
of cyclin B revealed similarly low levels of the protein in
both control and BI 2536-treated anaphase cells (Fig-
ure 3A). Consistent with previous reports (Lenart et al.,
2007; Sumara et al., 2004; van Vugt et al., 2004), this
experiment indicates that cyclin B is efficiently degradedInc.
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Plk1 Triggers Cytokinesis in Human CellsFigure 3. BI 2536 Treatment Does Not Prevent Cytokinesis via Elevated Cdk1 Activity
(A) Control metaphase and control anaphase cells (upper two panels) were analyzed for cyclin B levels by IFM. Cells treated with BI 2536 prior to
mitotic entry (‘‘Polo’’ prometaphase arrest) and BI 2536-treated anaphase cells (lower two panels) were processed in the same way. Percentages
indicate the fraction of cells at anaphase containing low levels of cyclin B among all cells scored at that cell-cycle stage (n = 100).
(B) HeLa cells synchronously released into anaphase were treated with control solvent, BI 2536 (20min after release), BMI-1026 (60min after release),
or a combination of BI 2536 and BMI-1026 (20 and 60min after release, respectively). Cells were analyzed 75 min (RhoA, anaphase), 120 min (tubulin,
telophase), and 12 hr (tubulin, interphase) after release by IFM. Percentages indicate the fraction of anaphase cells that contain equatorial RhoA stain-
ing (*), telophase cells displaying furrow ingression (**), and binucleate interphase cells (***) among all cells scored at the respective cell-cycle stage.despite Plk1 inhibition at anaphase. To corroborate this
hypothesis in a functional manner, we treated anaphase
cells with BI 2536, the Cdk1 inhibitor BMI-1026 (Seong
et al., 2003), or a combination of both drugs (Figure S2A).
BMI-1026 is known to rapidly abrogate the inhibition of cy-
tokinesis by Cdk1 even in the presence of high levels of
cyclin B (Niiya et al., 2005). If elevated activity of Cdk1 dur-
ing anaphase blocked cytokinesis in BI 2536-treated cells,
inhibition of Cdk1 should efficiently suppress this defect.
Contrary to this prediction, treatment of anaphase cells
with BMI-1026 did not rescue the Plk1 inhibition pheno-
type. Instead, cells treatedwith both Cdk1 andPlk1 kinase
inhibitors recapitulated all hallmarks of the BI 2536-
induced cytokinesis phenotype: failure of equatorial RhoA
localization at anaphase, defective furrow ingression in
telophase, and formation of binucleated cells uponmitotic
exit (Figure 3B). These results demonstrate that the cyto-
kinetic defects observed upon BI 2536 treatment at ana-
phase are not caused by a failure to inactivate Cdk1.
Plk1 Functions after Cdk1 Inactivation
to Trigger Cytokinesis
To confirm that Plk1 has a direct role in inducing cytokine-
sis following inactivation of Cdk1, we arrested cells at
prometaphase using low concentrations of the spindle
poison Nocodazole and then forced them to exit mitosis
by addition of the Cdk1 inhibitor BMI-1026 (Figure S2B).
In this assay, pharmacological downregulation of Cdk1
activity rapidly triggers the onset of cytokinetic events,
such as furrow ingression (Niiya et al., 2005). Due to the
Nocodazole-induced mitotic spindle defects, cytokinesisDeveis induced at multiple locations around the cortex, leading
to extensive ectopic furrowing prior to mitotic exit (Niiya
et al., 2005) (Figures 4A and 4B; Figure S2C; Movie S2).
As in normal cell divisions, ectopic furrowing during chem-
ical induction of cytokinesis depends on known cytokine-
sis regulators and is associated with accumulation of
RhoA at the tip of the incoming furrows (Niiya et al.,
2005). Crucially, addition of BI 2536 to Nocodazole-
arrested cells, which were forced to exit mitosis by Cdk1
inhibition, completely abolished ectopic furrow formation
and RhoA accumulation at the cortex but did not prevent
mitotic exit (Figures 4A and 4B; Figure S2C; Movie S2).
Forced mitotic exit and chemical induction of cytokine-
sis permit the analysis of early cytokinetic events even in
cases where depletion of a protein causes a SAC-induced
arrest at prometaphase. To test whether the BI 2536-
induced furrow ingression defect is caused by Plk1 inhibi-
tion, we arrested control siRNA- and Plk1 siRNA-trans-
fected cells in mitosis with Nocodazole and forced them
to exit mitosis by addition of BMI-1026 (Figure 4C; Fig-
ure S2B). Compared to control cells, depletion of Plk1 po-
tently blocked cortical RhoA accumulation and formation
of ectopic cleavage furrows (Figure 4C). Induction of a
monopolar spindle using the Eg5 kinesin inhibitor Monas-
trol (Mayer et al., 1999) did not interfere with ectopic fur-
rowing (Figures S2B and S2D), suggesting that the defects
observed in Plk1-depleted cells are not an indirect con-
sequence of Plk1’s function in bipolar spindle formation
(Lenart et al., 2007; McInnes et al., 2006; Peters et al.,
2006; Sumara et al., 2004; van Vugt et al., 2004). The
fact that depletion of Plk1 using gene-specific siRNAslopmental Cell 12, 713–725, May 2007 ª2007 Elsevier Inc. 717
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Plk1 Triggers Cytokinesis in Human CellsFigure 4. Plk1 Functions after Cdk1 Inactivation to Trigger Cytokinesis
(A) Nocodazole-arrested HeLa cells were treated with control solvent, BI 2536, BMI-1026, or a combination of BMI-1026 and BI 2536. Cells were
analyzed by phase-contrast microscopy (upper panels) or RhoA IFM (lower panels) 30 min after drug treatment. Percentage of mitotic cells that dis-
play ectopic furrowing 30 min after drug treatment is indicated (n = 100). Noc, Nocodazole.
(B) Selected frames from time-lapse series of HeLa cells expressing H2B-GFP. Nocodazole-arrested cells were treated with BMI-1026 or a combi-
nation of BMI-1026 and BI 2536 at time point t = 0 min just prior to recording. For full movie, see Movie S2. The percentage of cells displaying ectopic
furrowing among cells that exited mitosis is indicated (n = 55 for Noc BMI-1026, n = 54 for Noc BMI-1026 + BI 2536).
(C) Control siRNA- and Plk1 siRNA-transfected HeLa cells were arrested in mitosis by addition of Nocodazole and treated with BMI-1026. Cells were
analyzed by phase-contrast microscopy (upper panels) or RhoA IFM (lower panels) 30 min after drug treatment. The percentage of mitotic cells
displaying ectopic furrowing 30 min after drug treatment is indicated (n = 100). Immunoblot analysis of Plk1 and a-tubulin protein levels in extracts
prepared from control and Plk1 siRNA-transfected cells that were arrested in mitosis with Nocodazole is shown.reproduces one hallmark of the BI 2536-induced cytokine-
sis phenotype confirms the conclusions of our chemical
biology analysis. Taken together, our chemical epistasis718 Developmental Cell 12, 713–725, May 2007 ª2007 Elsevierexperiments using two kinase inhibitors demonstrates
that Plk1 activity specifically controls RhoA accumulation
and furrow ingression once Cdk1 has been inactivated.Inc.
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Its Own Catalytic Activity and Regulates Stable
Mklp2 and Chromosomal Passenger Localization
Like several other key regulators of cytokinesis, Plk1 local-
izes to the central spindle during anaphase and later con-
centrates around the midbody at telophase (Figure 5A)
(Barr et al., 2004; Eggert et al., 2006; Glotzer, 2005).
Plk1 has been shown to phosphorylate the central spin-
dle-associated kinesin Mklp2, thereby creating a binding
site for Plk1’s ownPBD and possibly promoting its own re-
cruitment to the midzone (Neef et al., 2003). This model
predicts that inhibition of Plk1 kinase activity should pre-
vent recruitment of the enzyme to the central spindle. Ad-
dition of BI 2536 to anaphase cells severely compromised
the localization of Plk1 to the midzone and midbody (Fig-
ure 5A), suggesting that Plk1 enzyme activity is indeed re-
quired for midzone recruitment of the kinase. Interestingly,
Plk1 inhibition also altered the distribution of Mklp2: it was
progressively lost from the central spindle during ana-
phase and accumulated at the equatorial cortex by telo-
phase (Figure 5B). This result indicates that Plk1 might
control Mklp2 function in vivo and is consistent with the
earlier finding that Mklp2 phosphorylation by Plk1 inhibits
Mklp2 microtubule bundling activity in vitro (Neef et al.,
2003). Relocation of chromosomal passenger complex
proteins, including Aurora B and Incenp (Eggert et al.,
2006; Glotzer, 2005), from kinetochores to the central
spindle at anaphase has been shown to also depend on
binding to Mklp2 (Gruneberg et al., 2004). Consistent
with this model, we observed localization defects for
both Aurora B and Incenp, which closely resemble the
one observed for Mklp2 (Figure 5B), after Plk1 inhibition
at anaphase (Figure 5C).
Interplay between Plk1 and Aurora B Function
in Cytokinesis
To test whether a gain-of-function effect by displaced Au-
rora B activity might be responsible for the early cytokine-
sis defect observed upon Plk1 inhibition, we performed
time-lapse analysis of cells synchronously released into
anaphase in the presence of BI 2536, the Aurora B inhib-
itor Hesperadin (Hauf et al., 2003), or a combination of
both drugs (Figure S2A). Addition of Hesperadin did not
ameliorate the BI 2536-induced defect and failed to con-
vert it to the somewhat weaker Aurora B inhibition pheno-
type (Figure 5D). Instead, combined inhibition of both Plk1
and Aurora B kinase at anaphase caused a fully penetrant
and more severe phenotype (Figure 5D), arguing against
the possibility that uncontrolled and delocalized Aurora
B activity is the reason for the early cytokinesis defect after
Plk1 inhibition. Furthermore, the combined effect of Plk1
and Aurora B inhibition implies that both kinases perform
at least partially independent functions to promote cyto-
kinesis in human cells.
Plk1 Promotes the Binding of the RhoGEF Ect2 to
HsCyk-4 and the Recruitment of Ect2 to the Midzone
To investigate how Plk1 triggers early cortical events dur-
ing cytokinesis, we examined the localization of theDevRhoGEF protein Ect2 and the two subunits of the central-
spindlin complex, Mklp1 and HsCyk-4, upon Plk1 inhibi-
tion at anaphase. In control cells, Ect2, Mklp1, and
HsCyk-4 accumulated at the central spindle at anaphase
(Figures 6A and 6B). Strikingly, BI 2536 treatment at ana-
phase selectively abolished the localization of Ect2 to the
central spindle without altering the accumulation of the
centralspindlin subunits HsCyk-4 and Mklp1, which are
known to recruit Ect2 to the midzone (Figures 6A and
6B). As in the case of HsCyk-4 and Mklp1, BI 2536 treat-
ment at anaphase did not alter the accumulation of the
microtubule bundling protein Prc1 (Eggert et al., 2006;
Glotzer, 2005) at the midzone (Figure 6D). Together with
the presence of a prominent microtubule array at the mid-
zone (Figures 6A, 6B, and 6D), these data suggest that
Plk1 is not essential for the formation of the central spindle
at anaphase.
The specific failure of Ect2 to localize to the midzone
raised the interesting possibility that Plk1 might trigger
the initiation of cytokinesis by promoting the interaction
of Ect2 with centralspindlin and, thereby, Ect2 activation
and recruitment to the central spindle. To test this, we pre-
pared protein lysates from cells synchronously released
from metaphase into anaphase in the presence or ab-
sence of BI 2536, immunoprecipitated Ect2, and probed
for copurification of its interaction partner HsCyk-4. Con-
sistent with published data (Nishimura and Yonemura,
2006; Yuce et al., 2005; Zhao and Fang, 2005), Ect2 tran-
siently but strongly bound to HsCyk-4 during anaphase
and telophase in lysates prepared from control cells,
whereas no binding was observed at metaphase (Fig-
ure 6C, lanes 1–4). Strikingly, inhibition of Plk1 at ana-
phase abolished the interaction between Ect2 and HsCyk-
4, despite efficient cell-cycle progression (Figure 6C, lanes
5–7). Semiquantitative immunoblotting revealed that BI
2536 reduced this interaction to well below 10% of the
level observed in control cells (data not shown). The loss
of the Ect2/HsCyk-4 protein interaction provides a molec-
ular explanation for the early cytokinesis defect observed
upon Plk1 inhibition at anaphase. Consistent with Plk1
localization to the midzone, our data indicate that Plk1
induces cleavage furrow ingression by promoting the as-
sociation of Ect2 with HsCyk-4 and, consequently, Ect2
recruitment to the central spindle (Figure 7).
DISCUSSION
Our pharmacological analysis of Plk1 during late mitosis
has revealed a previously unknown function for this key
mitotic kinase: triggering the initiation of cytokinesis in hu-
man cells. This workwas facilitated by the use of a specific
and highly potent small-molecule inhibitor (Lenart et al.,
2007; Steegmaier et al., 2007) that provided sufficient
temporal control over Plk1 activity to pinpoint essential
later mitotic roles of this kinase, which have hitherto
been obscured by its earlier functions. In addition, this
work emphasizes the advantages and growing impor-
tance of small-molecule inhibitors for cell biological
research.elopmental Cell 12, 713–725, May 2007 ª2007 Elsevier Inc. 719
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Plk1 Triggers Cytokinesis in Human CellsFigure 5. Plk1 Targeting to the Central Spindle Requires Its Own Catalytic Activity and Controls Stable Mklp2 and Chromosomal
Passenger Localization
(A) HeLa cells synchronously released into anaphase were treated with control solvent or BI 2536 20 min after release. Anaphase and telophase cells
were analyzed for the localization of Plk1 by IFM. Percentages indicate the fraction of cells displaying the phenotype represented by the image among
all cells scored at that cell-cycle stage (n = 100).
(B) Cells were processed as in (A) but analyzed for the localization of Mklp2.
(C) Cells were processed as in (A) but analyzed for the localization of Aurora B and Incenp.
(D) Quantification of a time-lapse series using HeLa cells expressing H2B-GFP. Cells synchronously released into anaphase were treated with control
solvent, BI 2536, Hesperadin, or a combination of BI 2536 andHesperadin prior to recording. Drugs were added 20min after release frommetaphase.
Cytokinesis phenotypes are shown as the percentage of the number of cells that exited mitosis during the time-lapse analysis (n = 51 for control,
n = 30 for BI 2536, n = 41 for Hesperadin, n = 60 for BI 2536 + Hesperadin). Hesp, Hesperadin.720 Developmental Cell 12, 713–725, May 2007 ª2007 Elsevier Inc.
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Plk1 Triggers Cytokinesis in Human CellsFigure 6. Plk1 Promotes the Binding of the RhoGEF Ect2 to HsCyk-4 and the Recruitment of Ect2 to the Midzone
(A) HeLa cells synchronously released into anaphase were treated with control solvent or BI 2536 (20min after release). Anaphase and telophase cells
were analyzed for the localization of Ect2 by IFM. Percentages indicate the fraction of cells displaying the phenotype represented by the image among
all cells scored at that cell-cycle stage (n = 100).
(B) Cells were processed as in (A) but analyzed for the localization of HsCyk-4 and Mklp1.
(C) Protein extracts prepared from cells arrested at metaphase (lane 1) and, at the indicated time points, from cells synchronously released into ana-
phase in the presence (lanes 5–7) or absence (lanes 2–4) of BI 2536 were subjected to immunoprecipitation using Ect2 antibodies and analyzed by
immunoblotting using Ect2 and HsCyk-4 antibodies. Time point 0 min indicates release frommetaphase. Drug treatment was performed 20 min after
release from metaphase. The percentages of anaphase and telophase cells and of telophase cells with furrow ingression as determined by IFM are
indicated below the corresponding lanes. IP, immunoprecipitated fraction.
(D) Cells were processed as in (A) but analyzed for the localization of Prc1.Although we cannot rule out that inhibition of other
kinases contributes to some of the phenotypes we ob-
served, two key points strongly support the hypothesisDevethat inhibition of Plk1 by BI 2536 is responsible for the
cytokinesis defect. First and foremost, depletion of Plk1
using a gene-specific method reproduced one cruciallopmental Cell 12, 713–725, May 2007 ª2007 Elsevier Inc. 721
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sions are substantiated by two independent studies,
which came to similar conclusions using a structurally dis-
tinct small-molecule inhibitor of Plk1 (A. Straight, personal
communication) and a genetically engineered ATP ana-
log-sensitive allele of Plk1 (Burkard et al., 2007).
Our results identify Plk1 as a key regulator of the Ect2/
HsCyk-4 complex that lies at the heart of cleavage furrow
induction in animal cells. We propose that Plk1’s key role
in triggering the initiation of cytokinesis in human cells is to
induce complex formation between Ect2 and HsCyk-4
(Figure 7). Formation of this complex is required for
RhoA activation and serves to localize the RhoGEF protein
Ect2 to the central spindle (Figure 7). Chemical epistasis
experiments have allowed us to show that this function
of Plk1 is required after inactivation of Cdk1. Once bound
to HsCyk-4, Ect2 could then locally activate the GTPase
RhoA, which would culminate in contractile ring formation
and cleavage furrow ingression at the equatorial cortex
(Figure 7) (Glotzer, 2005; Piekny et al., 2005). Thus, Plk1
likely plays a vital role in specifying the cleavage plane
and instructing human cells where and when to divide.
Consistent with the above model, Plk1 inhibition and
depletion of either Ect2 or HsCyk-4 result in a very similar
spectrum of early cytokinesis defects (Niiya et al., 2005;
Nishimura and Yonemura, 2006; Yuce et al., 2005; Zhao
and Fang, 2005): absence of contractile ring formation,
failure of equatorial RhoA accumulation and cleavage fur-
row ingression, and, finally, failure in ectopic furrowing
during forced mitotic exit. The Plk1 inhibition phenotype
closely resembles the one obtained by depletion of Ect2
or HsCyk-4 and is more severe than that observed upon
mere delocalization of the Ect2/HsCyk-4 complex (Nishi-
mura and Yonemura, 2006; Yuce et al., 2005; Zhao and
Fang, 2005). Hence, in addition to controlling GEF locali-
zation, Plk1-mediated complex formation presumably
contributes to the activation of Ect2’s GEF function. Our
finding that BI 2536 blocks Ect2 binding to HsCyk-4,
and Ect2 but not centralspindlin recruitment to the mid-
Figure 7. Model for Plk1 Function during Cytokinesis in
Human Cells
This model focuses on the role of Plk1 and does not represent a com-
prehensive overview of all regulatory pathways.722 Developmental Cell 12, 713–725, May 2007 ª2007 Elsevier Izone, indicates that Plk1 kinase activity might directly reg-
ulate this interaction. Recruitment of the kinase to themid-
zone at anaphase might increase the local concentration
of the enzyme and thereby direct Ect2/HsCyk-4 complex
formation to this subcellular location.
Ect2 activity itself and the Ect2/HsCyk-4 complex are
subject to phosphoregulation (Hara et al., 2006; Niiya
et al., 2006; Tatsumoto et al., 1999; Yuce et al., 2005).
Phosphorylation of Ect2 by Cdk1 inhibits complex forma-
tion and likely contributes to the inhibition of cytokinesis
before anaphase onset (Yuce et al., 2005) (Figure S3). In
contrast, phosphorylation of HsCyk-4 at unknown resi-
dues by an uncharacterized kinase might be crucial for
complex formation (Yuce et al., 2005). These HsCyk-4
modifications might provide a docking site for the
amino-terminal BRCT domains of Ect2, which mediate
HsCyk-4 binding (Somers and Saint, 2003; Yuce et al.,
2005) and can act as phosphopeptide binding modules
(Manke et al., 2003). Thus, it is tempting to speculate
that Plk1 is responsible for these phosphorylation events
on HsCyk-4 (Figure S3A). However, there is also evidence
supporting an alternative model. Ect2, similar to other
GEFs, can be regulated by intramolecular inhibition during
which the amino-terminal BRCT region binds to and in-
hibits the carboxy-terminal DH/GEF domain (Kim et al.,
2005). Phosphorylation of Ect2 by Plk1 during anaphase
might alleviate this intramolecular inhibition by dissociat-
ing the Ect2 amino from the carboxyl terminus (Fig-
ure S3B). This would set free the HsCyk-4 interaction do-
main and the GEF domain of Ect2 and could lead to both
targeting of Ect2 to the midzone and activation of its GEF
function. Consistent with this model, recent data have
suggested that phosphorylation of Ect2 might induce
a conformational change (Hara et al., 2006). Furthermore,
Plk1 has the ability to bind to Ect2 via the PBD and to
phosphorylate the GEF protein (Niiya et al., 2006). Future
work will be required to clarify whether Plk1 directly regu-
lates Ect2/HsCyk-4 complex formation, identify Plk1-de-
pendent phosphorylation sites on these proteins in vivo,
and analyze the molecular mechanism by which these
modifications might promote complex formation.
We show that localization of Plk1 to the midzone re-
quires its own catalytic activity rather than merely a prim-
ing event by Cdk1. This finding is in good agreement with
recent data on Plk1 targeting to centrosomes and kineto-
chores (Kang et al., 2006; Lenart et al., 2007). Moreover,
our analysis provides strong support for the existence of
a proposed anaphase pathway that involves Plk1,
Mklp2, and chromosomal passenger proteins (Gruneberg
et al., 2004; Neef et al., 2003) (Figure 7). Whereas Plk1 ap-
pears to be important for the stable localization of a subset
of central spindle-associated proteins, accumulation of
themicrotubule bundling protein Prc1 and the centralspin-
dlin complex subunits, Mklp1 and HsCyk-4, at the mid-
zone is independent of Plk1 (Figure 7). Thus, Plk1, in con-
trast to Aurora B (Hauf et al., 2003), is not essential for
central spindle formation.
Our discovery that Plk1 is essential for the initiation of
cytokinesis indicates that the deregulated levels of Plk1nc.
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Plk1 Triggers Cytokinesis in Human Cellsfound in a variety of human tumors (Steegmaier et al.,
2007) might promote aneuploidy not only by interfering
with spindle formation and chromosome segregation but
also by causing cytokinesis failure and subsequent tetra-
ploidization (Storchova and Pellman, 2004).
In budding yeast, the Polo-like kinase ortholog Cdc5
plays a central role in regulating mitotic exit by promoting
the release of the phosphatase Cdc14 from the nucleolus
during anaphase (Bardin and Amon, 2001). In contrast to
budding yeast, our data suggest that Plk1 activity at ana-
phase is not essential for mitotic exit in human cells.
The lack of conservation of a role of Plk1 in promoting
mitotic exit notwithstanding, the ‘‘Plk1/Ect2/Rho’’ path-
way that we have delineated in human cells bears remark-
able similarity to recently reported findings in budding
yeast. In this organism, localization of the GTPase Rho1
to the bud neck and subsequent formation of the contrac-
tile ring require phosphorylation of two GEF proteins by
Cdc5, the budding yeast Plk ortholog (Yoshida et al.,
2006). Consistent with observations in Drosophila (Car-
mena et al., 1998), this raises the exciting possibility that
a ‘‘Polo/GEF/Rho’’ module might represent an evolution-
arily conserved trigger for cytokinesis in yeast and animal
cells.
EXPERIMENTAL PROCEDURES
Cell Culture
HeLa ‘‘Kyoto’’ and HeLa H2B-GFP (Hirota et al., 2004) cells were
grown in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal calf serum (FCS), 0.2 mM L-glutamine, and antibiotics (all
Invitrogen). hTERT-RPE1 cells (Clontech) were grown in the same
medium, except that it also contained nonessential amino acids
(Biochrom).
Synchronization and Drug Treatments
Stocks of MG132 (Sigma), BI 2536 (Lenart et al., 2007; Steegmaier
et al., 2007), BMI-1026 (Seong et al., 2003), and Hesperadin (Hauf
et al., 2003) were prepared in DMSO. For all kinase inhibition experi-
ments, cell confluency was 70% or lower. For anaphase-specific
inhibition of Plk1 (see Figure 1A), HeLa cells were treated with 2 mM
thymidine (Sigma) for 24 hr, released for 6 hr, arrested in mitosis by ad-
dition of 50 ng/ml Nocodazole (Sigma) for 4 hr, transferred to medium
containing 10 mM MG132 for 2 hr, and then synchronously released
into anaphase. Drug-treated cells were washed twice with medium
when shifted to anothermedium. For all HeLa experiments (except Fig-
ures S1D and S1E), 100 nM BI 2536 was added 20 min after release
from metaphase. hTERT-RPE1 cells (Figure 1B) were arrested with
5 mM thymidine for 24 hr, released for 4.5 hr, arrested in mitosis by
addition of 50 ng/ml Nocodazole for 4 hr, and transferred to medium
containing 10 mM MG132 for 1.5 hr. After removal of MG132, mitotic
hTERT-RPE1 cells were shaken off, released into anaphase, and
treated with 250 nM BI 2536 115 min after release from metaphase.
For Aurora B inhibition at anaphase, 200 nM Hesperadin was added
20 min after release from metaphase (Figure S2A). For Cdk1 inhibition
at anaphase, 250 nM BMI-1026 was added 60 min after release from
metaphase (Figure S2A). For chemical induction of cytokinesis (Fig-
ure S2B), HeLa cells were treated with 2 mM thymidine for 24 hr, re-
leased for 6 hr, arrested in mitosis by addition of 30 ng/ml Nocodazole
for 6 hr, and then treatedwithmedium containing 30 ng/ml Nocodazole
plus 250 nM BMI-1026 and/or 100 nM BI 2536 as indicated. DMSO
was added at the appropriate concentration to all control samples.DevelPlk1 RNAi Experiment
HeLa cells were transfected with 150 nM control GL2 or Plk1 siRNA
duplexes (both Ambion) using Oligofectamine (Invitrogen) just prior
to treatment with 2 mM thymidine for 24 hr (Figure S2B). Cells were
released from thymidine for 6 hr, arrested in mitosis for 8 hr by addition
of 30 ng/ml Nocodazole, and finally shifted to medium containing
30 ng/ml Nocodazole and 250 nM BMI-1026. Monastrol (Mayer
et al., 1999) (Merck Biosciences) was included in the two Nocodazole
incubations at 100 mMas indicated. Protein extracts fromNocodazole-
arrested cells were analyzed by immunoblotting using primary mouse
monoclonal anti-Plk1 (clone F-8, Santa Cruz Biotechnology) (1:1,000)
and anti-a-tubulin (clone B-5-1-2, Sigma) (1:50,000) antibodies.
GL2 sense: 50-CGUACGCGGAAUACUUCGA-dTdT-30
Plk1 sense: 50-AACGAGCUGCUUAAUGACGAG-dTdT-30
Immunofluorescence Microscopy and Antibodies
Cells were grown on coverslips and fixed with 4% formaldehyde in
100 mM sodium phosphate buffer (pH 7.4) for 15 min at room temper-
ature (for anillin, cyclin B, and Mklp2 staining), with methanol at20C
overnight (for Aurora B, a-tubulin, Ect2, g-tubulin, Incenp, HsCyk-4,
Mklp1, Plk1, and Prc1 staining) or with 10% trichloroacetic acid on
ice for 15 min (for RhoA staining). For myosin II staining, cells were
fixed in myosin fixation buffer (80 mM PIPES [pH 6.8], 1 mM MgCl2,
0.2%Triton X-100, and 4% formaldehyde) for 15min at 37C. Antibody
staining was performed as described previously (Lenart et al., 2007).
Images were acquired on a Zeiss Axioplan 2 microscope using 403
Plan-Neofluar objective lenses (Carl Zeiss) equipped with a Cool-
SnapHQ CCD camera (Photometrics) controlled by Metamorph (Uni-
versal Imaging). Images were processed using Photoshop (Adobe).
Corresponding control and inhibitor treatment images were acquired
using identical settings.
The following primary antibodies were used: mouse monoclonal
anti-a-tubulin (clone B-5-1-2, Sigma) (1:10,000), rabbit anti-anillin
(Zhao and Fang, 2005) (1:10,000), mouse monoclonal anti-Aurora B
(AIM-1, BD Transduction Laboratories) (1:250), mouse monoclonal
anti-cyclin B1 (GNS1, Santa Cruz Biotechnology) (1:500), rabbit anti-
Ect2 (Yuce et al., 2005) (1:200), rabbit anti-g-tubulin (Sigma)
(1:4,000), rabbit anti-HsCyk-4 (Mishima et al., 2002) (1:100), rabbit
anti-Incenp (kindly provided by S. Hauf), rabbit anti-Mklp1 (Mishima
et al., 2002) (1:300), rabbit anti-myosin (nonmuscle) (Biomedical Tech-
nologies) (1:1,000), mouse monoclonal anti-Plk1 (clone F-8, Santa
Cruz Biotechnology) (1:100), rabbit anti-Prc1 (clone H-70, Santa
Cruz Biotechnology) (1:100), mouse monoclonal anti-RhoA (clone
26C4, Santa Cruz Biotechnology) (1:75), and rat monoclonal anti-
tubulin (clone YOL1/34, Serotec) (1:500). Highly crossadsorbed
secondary antibodies conjugated to Alexa 488, Alexa 568, or Alexa
633 (Molecular Probes) were used for detection.
Live Cell Imaging
HeLa Kyoto H2B-GFP cells were grown in LabTek I chambered cover-
glasses (Nunc). Cell synchronization and inhibitor treatments were per-
formed as described above. Before transferring to the microscope,
medium was changed to CO2-independent medium without phenol
red supplemented with 20% FCS, 0.2 mM L-glutamine, antibiotics,
and 1 mM Na pyruvate (all Invitrogen). Recording was started right af-
ter control solvent/100 nM BI 2536 addition (for Figure 1D and Movie
S1) and after 250 nM BMI-1026/100 nM BI 2536 addition (for
Figure 4B and Movie S2). Time-lapse frames were acquired using a
403 EC Plan-Neofluar objective on an Axiovert 200M Cell Observer
microscope (Zeiss) controlled by Metamorph software and equipped
with a heated XL 295 incubator full-enclosure chamber (Zeiss),
MS200 XY Piezo Z Stage (Applied Scientific Instrumentation), and
CoolSnapHQ CCD camera. GFP and bright-field or phase-contrast
frames were recorded every 2 min. H2B-GFP images are maximum-
intensity projections of six Z planes that were acquired 3 mm apart
(for Figure 1D and Movie S1) or of eight Z planes that were acquiredopmental Cell 12, 713–725, May 2007 ª2007 Elsevier Inc. 723
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Plk1 Triggers Cytokinesis in Human Cells5 mm apart (for Figure 4B and Movie S2). Time-lapse data were
processed using Metamorph and ImageJ (http://rsb.info.nih.gov/ij/)
software.
Immunoprecipitation
Anaphase-specific Plk1 inhibition in HeLa Kyoto cells was performed
as described above (Figure 1A). Immunoprecipitations from lysates
prepared at the indicated time points were performed and analyzed
as described previously (Yuce et al., 2005).
Supplemental Data
Supplemental Data include three figures and two movies and are
available at http://www.developmentalcell.com/cgi/content/full/12/5/
713/DC1/.
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